Tag - WB

William Blair launched coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with an “outperform” rating and risk-adjusted valuation of $16. The stock closed at $5.04 on Sept. 10. Analyst Matthew Phipps writes that his...